CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer

Li,Tianren; Xue,Hui; Guo,Yi; Guo,Kejun

doi:10.3892/or.2014.3045

CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer

Authors:
- Tianren Li
- Hui Xue
- Yi Guo
- Kejun Guo
View Affiliations

Affiliations: Department of Gynecology, The First Hospital of China Medical University, Shenyang 110001, P.R. China
Published online on: February 20, 2014 https://doi.org/10.3892/or.2014.3045
Pages: 1825-1831

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin-dependent kinase inhibitor 3 (CDKN3) has been reported to promote tumor genesis. Since it is unclear whether CDKN3 participates in the development of epithelial ovarian cancer (EOC), this study assessed the association between CDKN3 expression and cell biological functions, and demonstrated the clinical significance and prognosis of CDKN3 in EOC. CDKN3 expression was evaluated in 97 cases of tumor tissue by immunohistochemistry and in 60 tissues by western blotting. The clinical correlation was analyzed by Kaplan-Meier method and Cox hazards model. The molecular functional roles of CDKN3 in ovarian cancer cell line OVCAR3 were examined by small interfering RNA-mediated depletion of the protein followed by analyses of cell proliferation and invasion. Twenty-three out of 30 (76.7%) human EOC tissues exhibited stronger levels of CDKN3 protein compared with 10 out of 30 (33.3%) human ovarian surface epithelial (HOSE) tissues. The mean level of CDKN3 expression in the EOC tissues was 3.35-fold that in the HOSE tissues. CDKN3 protein was found to be overexpressed in 68.0% of the EOC samples and was correlated with poor patient survival (P<0.05). Furthermore, expression of CDKN3 was significantly associated with FIGO stage, recurrence and residual tumor size (P<0.05), and the CDKN3 status was a significant prognostic factor for EOC patients (P=0.005). In addition, depletion of CDKN3 expression inhibited the growth and clonogenic potential of the OVCAR3 cell line. Our present research found that CDKN3 may play an important role in the development and proliferation of EOC. CDKN3 may be used as a novel tumor marker to predict the prognosis of EOC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Dundr P: Ovarian carcinoma: current diagnostic principles. Cesk Patol. 46:53–61. 2010.(In Czech).
3	Seidman JD, Ronnett BM and Kurman RJ: Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 16:499–512. 2002. View Article : Google Scholar : PubMed/NCBI
4	Seidman JD and Kurman RJ: Pathology of ovarian carcinoma. Hematol Oncol Clin North Am. 17:909–925. vii2003. View Article : Google Scholar : PubMed/NCBI
5	Westfall D, Roma AA and Silva EG: High-grade serous carcinoma of the ovary. Ann Diagn Pathol. 13:285–290. 2009. View Article : Google Scholar : PubMed/NCBI
6	Vang R, Shih Ie M and Kurman RJ: Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 16:267–282. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tarin D: Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Rev. 31:21–39. 2012. View Article : Google Scholar : PubMed/NCBI
8	Patterson KI, Brummer T, O’Brien PM and Daly RJ: Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 418:475–489. 2009.PubMed/NCBI
9	Niculescu MD, Yamamuro Y and Zeisel SH: Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J Neurochem. 89:1252–1259. 2004. View Article : Google Scholar : PubMed/NCBI
10	Yeh CT, Lu SC, Chen TC, Peng CY and Liaw YF: Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma. Cancer Res. 60:4697–4700. 2000.PubMed/NCBI
11	Yeh CT, Lu SC, Chao CH and Chao ML: Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun. 305:311–314. 2003. View Article : Google Scholar : PubMed/NCBI
12	Blum R, Nakdimon I, Goldberg L, et al: E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer. 119:527–538. 2006. View Article : Google Scholar : PubMed/NCBI
13	Wu L, Timmers C, Maiti B, et al: The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 414:457–462. 2001. View Article : Google Scholar : PubMed/NCBI
14	Demetrick DJ, Matsumoto S, Hannon GJ, et al: Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet Cell Genet. 69:190–192. 1995. View Article : Google Scholar : PubMed/NCBI
15	MacDermed DM, Khodarev NN, Pitroda SP, et al: MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 3:162010. View Article : Google Scholar : PubMed/NCBI
16	Xing C, Xie H, Zhou L, et al: Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation. Biochem Biophys Res Commun. 420:29–35. 2012. View Article : Google Scholar : PubMed/NCBI
17	Taylor KJ, Sims AH, Liang L, et al: Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res. 12:R392010. View Article : Google Scholar : PubMed/NCBI
18	Lai MW, Chen TC, Pang ST and Yeh CT: Overexpression of cyclin-dependent kinase-associated protein phosphatase enhances cell proliferation in renal cancer cells. Urol Oncol. 30:871–878. 2012. View Article : Google Scholar : PubMed/NCBI
19	Wang L, Sun L, Huang J and Jiang M: Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif. 44:291–299. 2011. View Article : Google Scholar
20	Felisiak-Golabek A, Dansonka-Mieszkowska A, Rzepecka I, et al: p19 mRNA and protein expression as new prognostic factor in ovarian cancer patients. Cancer Biol Ther. 14:973–981. 2013. View Article : Google Scholar : PubMed/NCBI
21	No JH, Moon JM, Kim K and Kim YB: Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer. Gynecol Obstet Invest. 75:263–267. 2013. View Article : Google Scholar : PubMed/NCBI
22	Huang L, Wang HY, Li JD, et al: KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a. Cell Death Dis. 4:e7452013. View Article : Google Scholar : PubMed/NCBI
23	Bali A, O’Brien PM, Edwards LS, Sutherland RL, Hacker NF and Henshall SM: Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res. 10:5168–5177. 2004. View Article : Google Scholar : PubMed/NCBI
24	Lee SW, Reimer CL, Fang L, Iruela-Arispe ML and Aaronson SA: Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol. 20:1723–1732. 2000. View Article : Google Scholar : PubMed/NCBI
25	Chinami M, Yano Y, Yang X, et al: Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP). Cdk2cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of Cdk2. J Biol Chem. 280:17235–17242. 2005. View Article : Google Scholar : PubMed/NCBI
26	Yu Y, Jiang X, Schoch BS, Carroll RS, Black PM and Johnson MD: Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res. 67:130–138. 2007. View Article : Google Scholar : PubMed/NCBI
27	Lee J, Sung CO, Lee EJ, et al: Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. PLoS One. 7:e344562012. View Article : Google Scholar : PubMed/NCBI
28	Chen J, Jackson PK, Kirschner MW and Dutta A: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature. 374:386–388. 1995. View Article : Google Scholar : PubMed/NCBI
29	Barford D: The mechanism of protein kinase regulation by protein phosphatases. Biochem Soc Trans. 29:385–391. 2001. View Article : Google Scholar : PubMed/NCBI
30	Johnson LN, De Moliner E, Brown NR, et al: Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol Ther. 93:113–124. 2002. View Article : Google Scholar : PubMed/NCBI